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Background
Homeobox (HOX) genes, a family of transcription 
factors, function as key determinants of anterio-posterior 
patterning of animal embryos and the development of 
several organs [1]. Formed by gene duplication, 39 
members of the HOX gene family are arranged in four 
HOX clusters, A, B, C, and D on human chromosomes 7, 
17, 12, and 2, respectively. Altered HOX gene expression 
has been implicated in diﬀ  erentiation, invasion, epithelial-
mesenchymal transition, apoptosis, and receptor signal-
ing in a variety of cancer types [2-8]. In breast cancer, 
some HOX genes are overexpressed whereas others are 
underexpressed, and mutations are rarely observed [9]. 
However, the molecular mechanism of HOX gene action 
has remained elusive. Ten years after a study by Raman 
and colleagues [4] demonstrated that HOXA5 can 
control  p53 transcription and that loss of HOXA5 
correlated with loss of p53 expression in breast cancer, a 
study by Gilbert and colleagues [10] has pinpointed 
another gene critical for breast cell function, BRCA1, as 
the target of a HOX gene. In the latter study, the authors 
present strong evidence that HOXA9 inhibits breast 
cancer progression by modulating expression of BRCA1.
The paper
HOXA9 as a breast cancer-related gene piqued the 
interest of this group when an Aﬀ  ymetrix microarray 
analysis (Aﬀ   ymetrix, Santa Clara, CA, USA) of ﬁ  ve 
paired sets of microdissected breast tumors and their 
adjacent normal tissue identiﬁ   ed HOXA9 as 1 of 115 
transcripts that showed tumor-speciﬁ  c down  regulation. 
Examination of publicly available databases showed that 
HOXA9 is signiﬁ  cantly downregulated in breast cancer 
and correlated with disease aggressiveness. Th  e authors 
then went on to investigate the eﬀ  ects of HOXA9 re-
expression on tumor cell proliferation, survival, and 
diﬀ  erentiation. Interestingly, overexpression of HOXA9 
in estrogen receptor-negative cell lines inhibited breast 
cancer cells through decreases of cell growth, survival, 
and invasiveness and changes in morpho  genesis. In 
addition, to ﬁ   nd targets of HOXA9, the authors per-
formed global transcriptional proﬁ   ling of HOXA9-
overexpressing MDA-MD-231 cells. Th   ey found that the 
expression of BRCA1, the breast cancer susceptibility 
gene and a well-known tumor suppressor gene, was 
higher in HOXB9-overexpressing cells compared with 
vector control cells. By performing chromatin immuno-
precipitation analysis, they found that HOXA9 directly 
binds to the 5΄ promoter region of BRCA1. If HOXA9 is a 
regulator of tumor suppressor genes, they reasoned, loss 
of HOXA9 in nonmalignant MCF-10A mammary 
epithelial cells should lead to malignant transformation. 
To test this concept, the authors depleted HOXA9 in 
MCF10A cells with short hairpin RNAs (shRNAs). Th  is 
led to increases of cell growth, invasiveness, and survival 
phenotype. Similar changes were seen upon knockdown 
of BRCA1. Co-expression of HOXA9 with mutants of 
BRCA1 reduced the ability of HOXA9 to inhibit tumori-
genesis of breast cancer cells. In addition, by immuno-
histochemistry studies, the authors provide clinical 
evidence that there is a strong positive association 
between expression of HOXA9 and that of BRCA1. In 
summary, Gilbert and colleagues [10] demonstrated that 
HOXA9 inhibits cell proliferation and survival of human 
breast cancer cells, possibly by upregulation of BRCA1. 
Th  ese  ﬁ   ndings provide an explanation for the 
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© 2010 BioMed Central Ltdconcomitant loss of HOXA9 and BRCA1 expression in 
breast cancer.
Viewpoint
Previous studies have shown that HOXA9 is highly 
methylated and downregulated in several types of cancer, 
including breast cancer, but the consequences of this loss 
were not explored [11]. Th  e article by Gilbert and 
colleagues [10] clariﬁ   es, for the ﬁ   rst time, the clinical 
correlation and relevance of loss of HOXA9 and breast 
tumorigenesis. Second, the demonstration that shRNA-
mediated knockdown of HOXA9 promotes tumori  gene  sis 
in nonmalignant mammary epithelial cells supports the 
inference that, in normal cells, HOXA9 inhibits cell 
proliferation and survival of human breast cancer cells, 
possibly by upregulation of BRCA1. However, many 
questions remain. Can the loss of the HOXA9 gene alone 
disrupt homeostasis in breast cells and initiate/promote 
tumorigenesis? Do our experiments in tissue culture 
faithfully reﬂ  ect  in vivo events? In 1999, Chen and 
Capecchi [12] reported mild to no phenotypic changes in 
mammary glands of HOXA9/HOXB9/HOXD9 knockout 
mice; these triple-knockout female mice showed hypo-
plasia of the mammary glands but only upon induction of 
pregnancy and lactation; however, they did not develop 
tumors. In the article of Gilbert and colleagues [10], the 
arrayed tumor samples were from ﬁ  ve individuals ranging 
in age from 44 to 54 years and were presumably parous. 
Did parity play a role in heightening the eﬀ  ects of the loss 
of HOXA9 in their breast cells? Are HOXA9 and BRCA1 
also downregulated in nulliparous patients with breast 
cancer? Why do the other paralogs – HOXB9, C9, or D9 – 
not substitute for the function of the lost HOXA9? 
Perhaps HOXA9 is the only paralog speciﬁ  cally expressed 
in breast epithelial cells. Interestingly, as mentioned by 
the authors, HOXA9 is overexpressed and activated in 
acute myeloid leukemia and endothelial cells. But these 
cells do not show concomitantly high BRCA1 expression 
[13,14], supporting the dogma that HOX target genes are 
cell- and tissue-speciﬁ  c. In conclusion, the ﬁ  ndings in 
this paper are very informative, establishing the ability of 
HOXA9 to exert its vigilante function through regulating 
the expression of BRCA1 in breast cells. Th   e paper raises 
as many questions as it answers – a hallmark of an 
interesting paper.
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